US drug spending surged to almost $450B in 2023news2024-12-18T21:00:33+00:00December 18th, 2024|Endpoints News|
In surprise move, FDA’s No. 2 Bumpus to leave agency at end of 2024news2024-12-17T17:37:38+00:00December 17th, 2024|Endpoints News|
Pfizer projects stability for 2025 amid turbulence in DCnews2024-12-17T17:28:58+00:00December 17th, 2024|Endpoints News|
AstraZeneca denied full FDA approval of Andexxa after adcommnews2024-12-16T20:54:51+00:00December 16th, 2024|Endpoints News|
HRSA pushes back against another 340B rebate model, this time from Sanofinews2024-12-16T18:08:37+00:00December 16th, 2024|Endpoints News|
Neurocrine gets FDA approval in rare adrenal gland conditionnews2024-12-16T17:07:26+00:00December 16th, 2024|Endpoints News|
Checkpoint wins FDA approval of checkpoint inhibitor in advanced skin cancer, seeks partner for launchnews2024-12-16T16:23:12+00:00December 16th, 2024|Endpoints News|
Organon’s steroid-free cream Vtama wins approval in atopic dermatitisnews2024-12-13T20:53:06+00:00December 13th, 2024|Endpoints News|
FDA stands by mifepristone safety label in federal court challengenews2024-12-13T20:03:13+00:00December 13th, 2024|Endpoints News|
EMA’s committee says expanded label for Lilly’s Mounjaro into sleep apnea not necessarynews2024-12-13T17:40:54+00:00December 13th, 2024|Endpoints News|
